STOCK TITAN
  1. Home
  2. News
  3. IMMX

Immix Biopharma Inc - IMMX STOCK NEWS

Welcome to our dedicated news page for Immix Biopharma (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immix Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immix Biopharma's position in the market.

News
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) announces Dr. Sanchorawala joining Nexcella Scientific Advisory Board. Dr. Sanchorawala co-authored a study leading to daratumumab becoming a first-line standard of care for AL Amyloidosis. The company aims to advance NXC-201, a promising CAR-T therapy for relapsed/refractory AL Amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
management
-
News
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
Rhea-AI Summary
Immix Biopharma, Inc. (IMBX) announces Dr. Marko Radic joining Nexcella Scientific Advisory Board. Dr. Radic is a renowned expert in autoimmune CAR-T cell therapy and antibody-mediated disorders, bringing valuable experience to the company's subsidiary. His belief in the potential of NXC-201 for treating autoimmune diseases is a positive sign for the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
management
-
News
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) announced 100% overall response rate and 70% complete response rate in standard of care relapsed/refractory AL Amyloidosis patients with updated Phase 1/2 data. The best responder duration of response was 23.7 months, and the U.S. observed prevalence of relapsed/refractory AL Amyloidosis is growing 12% per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
News
Building Tranquility: The Home Depot Foundation Joins Forces To Address PTSD Struggles for Army Veteran
Rhea-AI Summary
Immix Biopharma, Inc. (Nasdaq:IMMX) has received FDA clearance for the Investigational New Drug (IND) application for BCMA CAR-T NXC-201, allowing the expansion of studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. The favorable tolerability of NXC-201 also enables potential expansion into autoimmune indications. 72 patients have been dosed with NXC-201 ex-U.S., showing promising overall response rates in both AL Amyloidosis and multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
none
-
News
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
Rhea-AI Summary
Immix Biopharma, Inc. (Nasdaq: IMMX) will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit on December 5, 2023. The company, a clinical-stage biopharmaceutical firm, focuses on personalized therapies for oncology and immunology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) will host a virtual KOL event on November 29, 2023, to discuss its BCMA-Targeted CAR-T cell therapy candidate NXC-201, in development for relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma with planned expansion into autoimmune indications. NXC-201 has shown promising Phase 1/2a data in ALA and R/R MM, with IND clearance to expand dosing into the U.S. and presentations at the American Society for Hematology 65th Annual Meeting. The therapy has also been awarded Orphan Drug Designation by the FDA in both AL Amyloidosis and multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
conferences
News
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) receives FDA clearance for IND application of BCMA CAR-T NXC-201, expanding studies to U.S. sites for relapsed/refractory AL Amyloidosis. Favorable tolerability allows potential expansion into autoimmune indications. 72 patients previously dosed with NXC-201 ex-U.S. have shown promising overall response rates in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
clinical trial fda approval
-
News
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
Rhea-AI Summary
Immix Biopharma, Inc. announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology Annual Meeting. NXC-201 is the only CAR-T being studied as a treatment for AL amyloidosis patients who relapsed or are refractory to daratumumab-CyBorD. The presentation will take place on December 10, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.73%
Tags
none
-
News
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
Rhea-AI Summary
Immix Biopharma, Inc. announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting. The data shows a 95% overall response rate in patients not previously treated with BCMA-targeted therapy and a 98% overall response rate in patients without extra-medullary disease. This could potentially increase demand for NXC-201 as CAR-T therapies are expected to be approved for earlier lines of treatment. The company's N-GENIUS technology platform aims to overcome toxicities associated with CAR-T therapies, allowing more hospitals to offer NXC-201.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.73%
Tags
none
News
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
Rhea-AI Summary
Dr. Michaela Liedtke joins Nexcella Scientific Advisory Board bringing decades of experience in hematology/oncology clinical trials and CAR-T cell therapy. Dr. Liedtke will contribute to the development of NXC-201, a promising CAR-T therapy for AL Amyloidosis and multiple myeloma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
management
Stock IMMX logo
Immix Biopharma Inc

Nasdaq:IMMX

IMMX Rankings

#4650 Ranked by Market Cap
#24 Ranked by Stock Gains
N/A Ranked by Dividends

IMMX Stock Data

72.85M
14.09M
45.91%
8.47%
1.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Los Angeles